본문 바로가기

바이오스펙테이터

기사본문

Vision of 'GenoFocus', Microbiome Engineering for New Drug

입력 2018-05-24 15:53 수정 2019-01-24 18:24

by Euna Lee

이 기사는 '프리미엄 뉴스서비스 BioS+' 기사입니다.

GenoFocus, an industrial and pharmaceutical enzyme development company, has recently been making a full-fledged effort to develop a new concept of microbiome drugs potentiated with enzyme combination.

Eui-Joong Kim, CEO of GenoFocus, introduced the specialty of the company, saying, “We have developed a system to identify therapeutic candidates from GRAS (generally recognized as safe) bacterial strains, and deliver them to the gastrointestinal (GI) tract. This is Spore Biologics using Bacillus spores. Spores are used as vehicles to deliver enzyme or protein drugs displayed on the spore surface.

More interestingly, spores reach the intestine safely and then produce therapeutic proteins or enzymes in situ.” Being transient passengers of the GI tract, but adapted to carry out their entire sporulation cycle within this environment. Bacillus spores are to germinate and release therapeutic proteins into the GI tract.

GenoFocus has been listed in the KOSDAQ market in 2015 as a new technology company, and has the platform technologies of ‘microbial display’ and ‘secretion expression’. Based on these core technologies, they have developed customized enzymes in various fields, such as food, medical and industrial enzymes. Among them, Lactase, Catalase, and Lipase are the representatives....

'프리미엄 뉴스서비스 BioS+'는 독자들에게 가치(value)있는 기사를 제공합니다.
추가내용은 유료회원만 이용할 수 있습니다.
회원이시면 로그인 해주시고, 회원가입을 원하시면 클릭 해주세요.
카카오스토리로 기사 공유하기